Scarica l'app Stockscreener
34.39
0.43%
-0.15
Dopo l'orario di chiusura:
34.11
-0.28
-0.81%
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus Target Price from Brokerages - MarketBeat
Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - The Globe and Mail
Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical - openPR
Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers - Barchart
Beta Thalassemia Market on Track for Major Expansion by 2034, - openPR
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expands By 8.0% - Defense World
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat
J.P. Morgan Notebook: Priorities For The Year Ahead - News & Insights
Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey
Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN
Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times
Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN
Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times
FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat
Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada
Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com
FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter
FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria
FDA approves label update for Agios's PYRUKYND - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):